Kenvue Inc. (NYSE:KVUE) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,337,978 shares of the company’s stock after selling 23,961 shares during the quarter. Rhumbline Advisers’ holdings in Kenvue were worth $71,266,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at about $29,000. Fortitude Family Office LLC lifted its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at about $35,000. Finally, Versant Capital Management Inc lifted its holdings in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent analyst reports. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Trading Up 2.3 %

Shares of Kenvue stock opened at $21.94 on Monday. The stock has a market cap of $42.07 billion, a P/E ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45. The stock’s 50 day simple moving average is $21.32 and its 200-day simple moving average is $22.09. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts predict that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.